Over the seven years since its STAR Market listing, Medicilon has supported nearly 700 candidates to secure IND approvals for clinical trials. Beyond this figure, a more profound shift is unfolding: China’s innovative drug industry is undergoing remarkable transformation. R&D has advanced from feasibility validation to clinical-stage development, and from China-only filings to global advancement — the fundamental value framework of the sector is being redefined. As a one-stop preclinical CRO platform for pharma, Medicilon has participated in and witnessed this industry-wide transition.
Shift 1: Diversification of Modalities — From Small Molecules to Novel Modalities, From Follow-on to Pioneering Innovation
In the early years, most Chinese INDs centered on conventional small molecule me-too candidates, which targeted well validated targets with fast follow strategies. As the industry matures, innovation has upgraded along the path: Me-too → Me-better → Best-in-class → First-in-class.
The pipeline landscape has expanded beyond small molecules into a rich portfolio of antibodies, ADCs, CGTs, peptides, small nucleic acids and other emerging modalities, marked by improved innovation quality and differentiation.
A stream of first-in-class and China-first programs have reached clinical milestones with Medicilon’s support:
- HG381 from HitGen: China’s first STING agonist to enter clinical development
- RGT-001 from Regor Therapeutics: World’s first candidate targeting an RNA helicase
- YY001 from Yuyao Biotech: China’s first novel, highly selective EP4 receptor antagonist
- LQ036 from Novamab: World’s first inhaled nanobody for moderate-to-severe asthma
- GT818 from GlueTacs Therapeutics: World-first RSK bifunctional degrader
- DXC014 from Dac Biotechnology: China’s first MUC1-targeted ADC
- KM501 from Xuanzhu Biopharm: China’s first FRα ADC and the world’s first afucosylated bispecific ADC
- IxCell PB-ZRAK from IxCell Biopharmaceuticals: World’s first CAR-raNK cell therapy
- Keprazan from Carephar: China’s first P-CAB potassium-competitive acid blocker
Today, innovation priorities lie in clinical value, differentiation and global competitiveness.
Shift 2: Expansion of Therapeutic Areas — Beyond Oncology to Broader Clinical Frontiers
Early Chinese pipelines were heavily concentrated in oncology, resulting in widespread homogeneity. While oncology remains the largest therapeutic area, R&D focus has shifted toward niche cancer subtypes, late-line resistant indications and precision patient populations.
Examples of differentiated programs supported by Medicilon include Medicovestor MC001 for pancreatic cancer, and MJC-001 oral paclitaxel soft capsule from Meji Biopharma for gastric, liver and other solid tumors, which overcomes limitations of conventional injectable formulations.
The metabolic and endocrine segment has seen explosive growth. Medicilon has supported 22 GLP‑1 candidates to obtain IND clearance. Notable programs include Hengrui’s HRS‑1596 for global development, WBD156 from Wayne Biotech and MDR‑001 from DRI Therapeutics.
Progress is also underway across neurology, autoimmunity, rare diseases, chronic hepatobiliary disorders, analgesia, anti-infectives and gout. Projects such as Hengrui SHR‑3201, Tasly TSL2402, Xinhua Pharmaceutical LXH‑2103, Hengqin Xinchuangyi F‑02‑2‑Na and Sungening SG1001 address unmet clinical needs with distinct mechanisms of action.
Shift 3: Evolving Filing Strategies — From Chinese Filings to Global Development & Accelerated Out-Licensing
Historically, developers mostly submitted INDs to NMPA first, with global expansion as a later option. Dual NMPA‑FDA IND filings have now become mainstream, while multi-jurisdictional synchronized submissions (China‑US‑EU, China‑Australia‑US) and early‑stage out‑licensing are increasingly common.
Medicilon has enabled dual China‑US IND approvals for assets including Meji Biopharma MJC‑001, GlueTacs Therapeutics GT818, Wayne Biotech WBD156, Sungening Biotech SG1001 and Hengqin Xinchuangyi F‑02‑2‑Na. It also supported triple filings (China‑US‑Australia) for ZT002 from QL Biopharm and T320 ADC from Nanolattix.
In addition, 27 innovative assets backed by Medicilon’s preclinical services have completed overseas out‑licensing deals. Highlights include YL201 / YL202 (B7H3 ADCs, MediLink Therapeutics), JYB1904 (long‑acting IgE antibody, Jeyou Pharma), Hengrui HRS‑753 (GLP‑1), almonertinib ( Allist Pharmaceuticals), and XNW27011 (Claudin18.2 ADC, Evopoint Biosciences). Covering ADCs, antibodies, GLP‑1s and small molecules, these cases demonstrate that high-quality preclinical research underpins successful global out‑licensing.
Shift 4: Reset Value Metrics — From Chasing IND Counts to High-Quality Innovation
The industry once prioritized IND numbers as a core KPI. The market now recognizes that an IND is merely the starting point of drug development. Scientists pay greater attention to druggability, differentiation, clinical translatability and commercial viability. The share of homogeneous me‑too projects is declining, while First‑in‑Class, Best‑in‑Class, formulation and delivery innovations are on the rise. More pioneering candidates secure BD out‑licensing as early as the IND stage, allowing capital markets to recognize the commercial value of original innovation at an earlier phase.
Nearly 700 IND approvals bear witness to the breakthroughs of China’s innovative drug industry, as well as Medicilon’s seven years of dedication and global collaboration since its STAR Market listing.
The journey continues. Medicilon will keep partnering with innovative biotech firms. Leveraging its full technology portfolio and Target to IND preclinical service capabilities, we help more novel therapies advance into clinical trials.